{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:03:38Z","timestamp":1770077018370,"version":"3.49.0"},"reference-count":14,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2015,7,2]]},"abstract":"<jats:p>Agranulocytosis is a rare but serious adverse effect of sulfasalazine treatment. We present a case of a 51-year-old woman receiving sulfasalazine for inflammatory arthritis presenting with sore throat, fever, lethargy and leucopenia (white cell count 0.9\u00d710<jats:sup>9<\/jats:sup>\/L). After 9\u2005days of treatment with filgrastim (granulocyte-colony stimulating factor, G-CSF), her white cell count increased to 77.4\u00d710<jats:sup>9<\/jats:sup>\/L. This case highlights the importance of recognising sulfasalazine-induced agranulocytosis and the management of hyperleucocytosis following G-CSF treatment, to prevent harmful sequelae.<\/jats:p>","DOI":"10.1136\/bcr-2015-210709","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T12:03:51Z","timestamp":1436961831000},"page":"bcr2015210709","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Hyperleucocytosis following G-CSF treatment for sulfasalazine-induced agranulocytosis"],"prefix":"10.1136","volume":"2015","author":[{"given":"Kenneth","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redwan","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.1","unstructured":"Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE clinical guideline; February, 2009. https:\/\/www.nice.org.uk\/guidance\/cg79 (accessed 11 Jul 2015)."},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.3","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3282f15fb9"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/j.1875-9114.1995.tb04352.x","article-title":"The risk of sulfasalazine- and mesalazine-associated blood disorders","volume":"15","author":"Jick","year":"1995","journal-title":"Pharmacotherapy"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2036.1995.tb00443.x","article-title":"Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor","volume":"9","author":"Roddie","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.7","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.4.299.30941"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00009"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701090"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.10","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K093"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0364-9"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703138"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.13","first-page":"46","article-title":"Therapeutic leukapheresis: 9-year experience in a University Hospital","volume":"13","author":"Parra Salinas","year":"2015","journal-title":"Blood Transfus"},{"key":"2025042706480133000_2015.jul15_1.bcr2015210709.14","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.V89.8.2736","article-title":"Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor","volume":"89","author":"Roberts","year":"1997","journal-title":"Blood"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2015-210709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:48:07Z","timestamp":1745761687000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2015-210709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,15]]},"references-count":14,"alternative-id":["10.1136\/bcr-2015-210709"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2015-210709","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,15]]}}}